Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched-cohort study

Hind T. Hatoum, Swu Jane Lin, Medha Sasane, Jonathan Trent

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Data are limited on the use of adjuvant imatinib in patients with gastrointestinal stromal tumor (GIST) outside of clinical trials. This retrospective, population-based, matched-cohort study evaluated adjuvant imatinib treatment patterns, assessed impact on clinical outcomes, and estimated effectiveness based on number needed to treat (NNT). Research design and methods: GIST-related claims from the PharMetrics claims database were included (20002010). A stepwise identification algorithm identified appropriate patients based on GIST-related ICD-9-CM codes, who were classified as 'imatinib (IM) patients' receiving imatinib within 84 days post-surgery and 'non-imatinib (non-IM) patients' undergoing surgery but not receiving imatinib during the study period. The primary composite outcome was based on incidence of a second GIST-related surgery and long-term follow-up in the matched cohorts. IM patients were matched with up to eight non-IM patients on age, gender, ICD-9-CM code, and first surgery date. Results: A total of 118 IM and 4088 non-IM patients with possible GIST ICD-9s and surgery were included. The median duration between first and second surgeries was significantly longer in IM than non-IM patients (488vs. 290 days; p0.0005). IM patients also had longer median follow-up from initial surgery to composite outcome (433vs. 320 days; p0.002). Adherence to IM, measured by medication possession ratio, was 0.83 and 0.73 during the first and second years of treatment, respectively. IM patients were less likely to have the composite outcome compared with non-IM patients (hazard ratio0.501; p0.0005). The NNT to prevent one outcome was 4. Conclusions: Patients receiving adjuvant imatinib treatment were less likely to have second surgery or be lost to follow-up, and had a longer interval to second surgery. Although treatment with adjuvant imatinib in patients with primary GIST is effective, adherence to imatinib and treatment duration are less than recommended by current treatment guidelines.

Original languageEnglish
Pages (from-to)805-814
Number of pages10
JournalCurrent Medical Research and Opinion
Volume28
Issue number5
DOIs
StatePublished - May 1 2012

Fingerprint

Gastrointestinal Stromal Tumors
Cohort Studies
Population
Numbers Needed To Treat
International Classification of Diseases
Imatinib Mesylate
Therapeutics
Lost to Follow-Up
Ambulatory Surgical Procedures

Keywords

  • Adjuvant drug therapy
  • Gastrointestinal stromal tumors
  • Imatinib
  • Outcomes assessment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor : Results of a population-based, matched-cohort study. / Hatoum, Hind T.; Lin, Swu Jane; Sasane, Medha; Trent, Jonathan.

In: Current Medical Research and Opinion, Vol. 28, No. 5, 01.05.2012, p. 805-814.

Research output: Contribution to journalArticle

@article{728650e4510f4b5395e0206ff39322e5,
title = "Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched-cohort study",
abstract = "Objective: Data are limited on the use of adjuvant imatinib in patients with gastrointestinal stromal tumor (GIST) outside of clinical trials. This retrospective, population-based, matched-cohort study evaluated adjuvant imatinib treatment patterns, assessed impact on clinical outcomes, and estimated effectiveness based on number needed to treat (NNT). Research design and methods: GIST-related claims from the PharMetrics claims database were included (20002010). A stepwise identification algorithm identified appropriate patients based on GIST-related ICD-9-CM codes, who were classified as 'imatinib (IM) patients' receiving imatinib within 84 days post-surgery and 'non-imatinib (non-IM) patients' undergoing surgery but not receiving imatinib during the study period. The primary composite outcome was based on incidence of a second GIST-related surgery and long-term follow-up in the matched cohorts. IM patients were matched with up to eight non-IM patients on age, gender, ICD-9-CM code, and first surgery date. Results: A total of 118 IM and 4088 non-IM patients with possible GIST ICD-9s and surgery were included. The median duration between first and second surgeries was significantly longer in IM than non-IM patients (488vs. 290 days; p0.0005). IM patients also had longer median follow-up from initial surgery to composite outcome (433vs. 320 days; p0.002). Adherence to IM, measured by medication possession ratio, was 0.83 and 0.73 during the first and second years of treatment, respectively. IM patients were less likely to have the composite outcome compared with non-IM patients (hazard ratio0.501; p0.0005). The NNT to prevent one outcome was 4. Conclusions: Patients receiving adjuvant imatinib treatment were less likely to have second surgery or be lost to follow-up, and had a longer interval to second surgery. Although treatment with adjuvant imatinib in patients with primary GIST is effective, adherence to imatinib and treatment duration are less than recommended by current treatment guidelines.",
keywords = "Adjuvant drug therapy, Gastrointestinal stromal tumors, Imatinib, Outcomes assessment",
author = "Hatoum, {Hind T.} and Lin, {Swu Jane} and Medha Sasane and Jonathan Trent",
year = "2012",
month = "5",
day = "1",
doi = "10.1185/03007995.2012.685928",
language = "English",
volume = "28",
pages = "805--814",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor

T2 - Results of a population-based, matched-cohort study

AU - Hatoum, Hind T.

AU - Lin, Swu Jane

AU - Sasane, Medha

AU - Trent, Jonathan

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Objective: Data are limited on the use of adjuvant imatinib in patients with gastrointestinal stromal tumor (GIST) outside of clinical trials. This retrospective, population-based, matched-cohort study evaluated adjuvant imatinib treatment patterns, assessed impact on clinical outcomes, and estimated effectiveness based on number needed to treat (NNT). Research design and methods: GIST-related claims from the PharMetrics claims database were included (20002010). A stepwise identification algorithm identified appropriate patients based on GIST-related ICD-9-CM codes, who were classified as 'imatinib (IM) patients' receiving imatinib within 84 days post-surgery and 'non-imatinib (non-IM) patients' undergoing surgery but not receiving imatinib during the study period. The primary composite outcome was based on incidence of a second GIST-related surgery and long-term follow-up in the matched cohorts. IM patients were matched with up to eight non-IM patients on age, gender, ICD-9-CM code, and first surgery date. Results: A total of 118 IM and 4088 non-IM patients with possible GIST ICD-9s and surgery were included. The median duration between first and second surgeries was significantly longer in IM than non-IM patients (488vs. 290 days; p0.0005). IM patients also had longer median follow-up from initial surgery to composite outcome (433vs. 320 days; p0.002). Adherence to IM, measured by medication possession ratio, was 0.83 and 0.73 during the first and second years of treatment, respectively. IM patients were less likely to have the composite outcome compared with non-IM patients (hazard ratio0.501; p0.0005). The NNT to prevent one outcome was 4. Conclusions: Patients receiving adjuvant imatinib treatment were less likely to have second surgery or be lost to follow-up, and had a longer interval to second surgery. Although treatment with adjuvant imatinib in patients with primary GIST is effective, adherence to imatinib and treatment duration are less than recommended by current treatment guidelines.

AB - Objective: Data are limited on the use of adjuvant imatinib in patients with gastrointestinal stromal tumor (GIST) outside of clinical trials. This retrospective, population-based, matched-cohort study evaluated adjuvant imatinib treatment patterns, assessed impact on clinical outcomes, and estimated effectiveness based on number needed to treat (NNT). Research design and methods: GIST-related claims from the PharMetrics claims database were included (20002010). A stepwise identification algorithm identified appropriate patients based on GIST-related ICD-9-CM codes, who were classified as 'imatinib (IM) patients' receiving imatinib within 84 days post-surgery and 'non-imatinib (non-IM) patients' undergoing surgery but not receiving imatinib during the study period. The primary composite outcome was based on incidence of a second GIST-related surgery and long-term follow-up in the matched cohorts. IM patients were matched with up to eight non-IM patients on age, gender, ICD-9-CM code, and first surgery date. Results: A total of 118 IM and 4088 non-IM patients with possible GIST ICD-9s and surgery were included. The median duration between first and second surgeries was significantly longer in IM than non-IM patients (488vs. 290 days; p0.0005). IM patients also had longer median follow-up from initial surgery to composite outcome (433vs. 320 days; p0.002). Adherence to IM, measured by medication possession ratio, was 0.83 and 0.73 during the first and second years of treatment, respectively. IM patients were less likely to have the composite outcome compared with non-IM patients (hazard ratio0.501; p0.0005). The NNT to prevent one outcome was 4. Conclusions: Patients receiving adjuvant imatinib treatment were less likely to have second surgery or be lost to follow-up, and had a longer interval to second surgery. Although treatment with adjuvant imatinib in patients with primary GIST is effective, adherence to imatinib and treatment duration are less than recommended by current treatment guidelines.

KW - Adjuvant drug therapy

KW - Gastrointestinal stromal tumors

KW - Imatinib

KW - Outcomes assessment

UR - http://www.scopus.com/inward/record.url?scp=84861131012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861131012&partnerID=8YFLogxK

U2 - 10.1185/03007995.2012.685928

DO - 10.1185/03007995.2012.685928

M3 - Article

C2 - 22506625

AN - SCOPUS:84861131012

VL - 28

SP - 805

EP - 814

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 5

ER -